The inhaled drug manufacturer’s directors describe the bid as “fair and reasonable.”Read More
New division will identify and invest in companies in emerging industries.Read More
The private equity firm’s bid for Vectura remains lower than that made by PMI. Read More
The move underlines the company’s commitment to Canada, says CEORead More
The acquisition is the company’s third non-tobacco deal in short succession. Read More
The move comes after a counteroffer from Carlyle for the drug delivery solutions provider. Read More
The company invests in production, testing and people ahead of projected demand.Read More
The company anticipates greater demand for its products as it launches in new markets. Read More
Government is uncomfortable with a tobacco firm 'profiting from respiratory ailments.' Read More
The deal expands PMI's product development capabilities in inhaled therapeutics.Read More
